Build Western ytterbium-176 enrichment so lutetium-177 has more than one supplier
The lutetium used in approved prostate and neuroendocrine cancer treatments is made from an enriched metal that comes mostly from Russia. Making it elsewhere would secure supply.
Overview
No-carrier-added lutetium-177 is produced by irradiating enriched ytterbium-176, most of which has historically come from Russian electromagnetic separators. Demand is rising steeply with Pluvicto, Lutathera and pipeline radioligands. Several companies (ASP Isotopes, ITM, SHINE and others) are developing laser or centrifuge enrichment in North America and Europe. The proposal is an advance market commitment by health systems and manufacturers to buy a guaranteed volume of Western-enriched ytterbium-176 at a floor price for ten years, with a strategic buffer stock, mirroring how vaccine advance commitments created capacity.
- Manufacturing cost and time for living and radioactive medicines · Cell therapies take weeks to make for one patient and cost hundreds of thousands of dollars. Isotopes run short.
Similar pages
not linked directly; found by shared links- IdeaRegional radiopharmacy hubs and harmonised transport rules for short-lived isotopes
Shares Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium, Manufacturing cost and time for living and radioactive medicines, Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan.
- IdeaA coordinated reserve and shared schedule for the world's medical isotope reactors
Shares Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium, Manufacturing cost and time for living and radioactive medicines, Radioligand therapy (beta emitters), Lutetium-177.
- TrialStudy to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
Shares Novartis, Lutetium-177 dotatate, Lutetium-177.
- BottleneckHot lab and shielded treatment room capacity
Shares ITM Isotope Technologies Munich, Novartis, Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan.
- IdeaA global medical isotope supply observatory with forecasts and shortage alerts
Shares Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium, Manufacturing cost and time for living and radioactive medicines, Radioligand therapy (beta emitters), Lutetium-177.
- TrialStudy of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Shares Novartis, Lutetium-177 vipivotide tetraxetan, Lutetium-177.
- CompanyNTP Radioisotopes
Shares Enriched target material for therapeutic isotopes, Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium, Lutetium-177.
- TrialAn Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC
Shares Novartis, Lutetium-177 vipivotide tetraxetan, Lutetium-177.